Citation Impact
Citing Papers
Molecular Imaging of the Efficacy of Heat Shock Protein 90 Inhibitors in Living Subjects
2008
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green
2018 StandoutNobel
Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
2015
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
2009
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
2008
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
2015
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
TOR Signaling in Growth and Metabolism
2006 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
2010
Design and synthesis of ansamycin antibiotics
2008
Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA
2009
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Targetable HPMA Copolymer–Aminohexylgeldanamycin Conjugates for Prostate Cancer Therapy
2009
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR
2015 Standout
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
2006
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Cystic fibrosis
2016 Standout
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Akt-regulated pathways in prostate cancer
2005
A Selenium Analogue of Firefly D ‐Luciferin with Red‐Shifted Bioluminescence Emission
2012 StandoutNobel
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Treatment of Obesity with Celastrol
2015 Standout
New approaches to molecular cancer therapeutics
2006
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Heat shock protein 90: The cancer chaperone
2007
HSP90 and the chaperoning of cancer
2005 Standout
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
2012
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
1997 Standout
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
1997 Standout
Development and validation of a rapid and sensitive high-performance liquid chromatography–mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma
2008
Anesthesiology
1997 Standout
Remifentanil
1996
Molecular chaperones in protein folding and proteostasis
2011 StandoutNature
Synthesis, crystal structures and cytotoxicities of some transition metal complexes with N-[2-{(pyridin-2-ylmethylidene)amino}ethyl]acetamide
2006
RACK1 Competes with HSP90 for Binding to HIF-1α and Is Required for O2-Independent and HSP90 Inhibitor-Induced Degradation of HIF-1α
2007 StandoutNobel
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
The CDK inhibitors in cancer research and therapy
2011
Inhibitors of the HSP90 Molecular Chaperone: Current Status
2006
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter
1995
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Paclitaxel and its formulations
2002 Standout
Cell cycle kinases as therapeutic targets for cancer
2009
Pharmacokinetics of biliary excretion in man. VI. Indocyanine green
1988
Development and application of Hsp90 inhibitors
2007
Tumor Angiogenesis
2008 Standout
Update on tubulin-binding agents
2005
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Lung Microbiota and Bacterial Abundance in Patients with Bronchiectasis when Clinically Stable and during Exacerbation
2013
Natural Products as Leads to Potential Drugs: An Old Process or the New Hope for Drug Discovery?
2008
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Sumatriptan: a decade of use and experience in the treatment of migraine
2004
Targeting the mTOR Signaling Network for Cancer Therapy
2009
Development of synthetic routes to macrocyclic compounds based on the HSP90 inhibitor radicicol
2006
Marine Indole Alkaloids: Potential New Drug Leads for the Control of Depression and Anxiety
2010 Standout
New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
2011
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
2014
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry
2007 Standout
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
2006
Mechanistic Insight into the Inhibition of Matrix Metalloproteinases by Platinum Substrates
2009
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
1993
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
2011 Standout
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
2005
Inhibitors of the mammalian target of rapamycin
2005
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
2009
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
2005
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Confinement-Controlled, Either syn- or anti-Selective Catalytic Asymmetric Mukaiyama Aldolizations of Propionaldehyde Enolsilanes
2021 StandoutNobel
Works of Anne O’Donnell being referenced
Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
2004
A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)
2003
Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours
2004
Airway drug pharmacokinetics via analysis of exhaled breath condensate
2013
Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra-Short-Acting Opioid
1993
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points
2005
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
2006
Sumatriptan Absorption from Different Regions of the Human Gastrointestinal Tract
1995
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection
1992
Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in Bronchiectasis
2000
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
2005
The Pharmacokinetic Basis for H2-antagonist Drug Interactions
1983
ANALGESIC EFFICACY OF SINGLE ESCALATING DOSES OF G187084B ADMINISTERED INTRAVENOUSLY TO HEALTHY ADULT MALE VOLUNTEERS
1991
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
2008
Lack of Effect of Histamine H2‐Receptor Antagonists on Indocyanine Green Disposition Measured by Two Methods
1984
Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers
2004